Evidence map›Paper›PMID 42440757›Full record

ArticleRSC advances2026

Imidazopyridine derivatives as promising anti-

Ahmed Sabt, Hend Okasha, Hanaa Farag, Zeinab H Fahmy, Eman A H Selim, Hoda Atef Abdelsattar Ibrahim, Mohamed G Thabit, Abdullah F Radwan, Wagdy M Eldehna, Reham R Mostafa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed SabtChemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre Dokki Cairo 12622 Egypt sabt.nrc@gmail.com.ORCID https://orcid.org/0000-0001-6976-0196
Hend OkashaBiochemistry and Molecular Biology Department, Theodor Bilharz Research Institute Giza Egypt.ORCID https://orcid.org/0000-0003-1125-245X
Hanaa FaragPesticide Chemistry Department, Chemical Industries Research Institute, National Research Centre Cairo Egypt.ORCID https://orcid.org/0000-0002-5666-3765
Zeinab H FahmyDepartment of Parasitology, Theodor Bilharz Research Institute Giza Egypt.
Eman A H SelimDepartment of Parasitology, Theodor Bilharz Research Institute Giza Egypt.
Hoda Atef Abdelsattar IbrahimPediatric Department, Faculty of Medicine, Cairo University Cairo Egypt.ORCID https://orcid.org/0000-0001-5399-8861
Mohamed G ThabitDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University (PUA) Alexandria Egypt.ORCID https://orcid.org/0000-0002-2360-294X
Abdullah F RadwanDepartment of Biochemistry, Faculty of Pharmacy, Egyptian Russian University Badr City 11829 Cairo Egypt.ORCID https://orcid.org/0000-0002-3731-1561
Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University Kafrelsheikh 33516 Egypt wagdy2000@gmail.com.ORCID https://orcid.org/0000-0001-6996-4017
Reham R MostafaDepartment of Medical Parasitology, Faculty of Medicine, Cairo University Cairo Egypt.ORCID https://orcid.org/0000-0003-1049-3147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis continues to pose significant challenges to public health and animal husbandry, thereby generating an ongoing need for the development of novel therapies through innovative approaches. In response to the persistent pursuit of an optimal chemotherapeutic agent, the present study designed and synthesized new small molecules (6 and 9a-d) featuring an imidazopyridine scaffold linked to isatin derivatives

Identifiers

PMID42440757
PMCPMC13334276

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.